U.S. stock night trading opens with fluctuations: Icon Energy drops 8.97% in night trading; CG oncology rises 8.36% in night trading

U.S. Stock Night Market Opening Movements Icon Energy fell 8.97% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. CG Oncology rose 8.36% in the night market. Based on recent key news: On January 10, CG Oncology announced that the late-stage trial of its main asset cretostimogene grenadenorepvec is expected to produce top-line data in the first half of 2026, nearly a year earlier than previously planned. The accelerated trial enrollment has led to an earlier timeline, driving the stock price up by about 31%. Source: Reuters On January 10, analyst Slutsky directly incorporated the medium-risk NMIBC opportunity into CG Oncology's valuation framework, raising its stock price target to $108 per share, reflecting a higher risk-adjusted value. Source: Bloomberg On January 10, analyst Roy pointed out that CG Oncology's enterprise value is approximately $3.3 billion, relative to its risk-adjusted peak sales estimate of about $5.2 billion, considering the company an attractive acquisition candidate. Source: Morgan Stanley. The biopharmaceutical industry has performed strongly recently, with significant capital inflows. Top Gainers in the U.S. Night Market Bark rose 26.07% in the night market. Based on recent key news: On January 9, Bark Inc. received a preliminary non-binding privatization proposal from Great Dane Ventures to acquire all outstanding shares at $0.90 per share. This news drove the stock price up as investors anticipated a possible acquisition premium. On January 9, Bark Inc.'s board established a special committee to evaluate the merits of the proposal. This move shows the company's seriousness about the proposal, further boosting market confidence. On January 9, Bark Inc. submitted relevant documents to the SEC detailing the proposal and the involved shareholders, including CEO Matt Meeker. This increased transparency reduces market uncertainty. The market has reacted positively to acquisition news recently, with significant capital inflows. Day One Biopharmaceuticals rose 19.69% in the night market. Based on recent news, On January 11, Day One Biopharmaceuticals announced preliminary data on net product revenue for OJEMDA™ for 2025 and provided guidance for net product revenue in 2026. The company expects net product revenue for OJEMDA in the U.S. to reach $225 million to $250 million in 2026. This optimistic revenue expectation significantly boosted the stock price On January 11, the company released the above information through GlobeNewswire, further enhancing market confidence in its future performance. On January 11, despite facing global macroeconomic uncertainties and potential operational risks, Day One Biopharmaceuticals demonstrated its strong capabilities in product development and commercialization, leading to optimism among investors. The biopharmaceutical industry has recently performed strongly, with increasing market demand for innovative drugs. Gossamer Bio rose 19.60% in after-hours trading. Based on recent key news: On January 9, Guggenheim maintained a hold rating on Gossamer Bio, despite the analyst consensus being a strong buy, with a target price of $12.33, representing a 393.20% upside from current levels. This rating could have a positive impact on the stock price. On January 8, Gossamer Bio's Chief Operating Officer and Chief Financial Officer Bryan Giraudo mentioned information related to pulmonary arterial hypertension in the company's news, which may trigger market attention on the company's products and drive the stock price up. The biotechnology industry has been active recently, with significant capital inflows